Susquehanna International Group
DNTH icon

Susquehanna International Group’s Dianthus Therapeutics DNTH Stock Holding History

Susquehanna International Group’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.5M Buy
65,500
+46,100
+238% +$2.67M ﹤0.01% 4071
2025
Q4 		$799K Sell
19,400
-122,800
-86% -$4.76M ﹤0.01% 7681
2025
Q3 		$5.6M Buy
142,200
+111,000
+356% +$2.84M ﹤0.01% 3893
2025
Q2 		$581K Buy
+31,200
New +$585K ﹤0.01% 8822
2021
Q2 		– Sell
-1,700
Closed -$322K – 12672
2021
Q1 		$322K Buy
+1,700
New +$286K ﹤0.01% 10453

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group's DNTH Position: Q1 2026 in Review

Susquehanna International Group increased its Dianthus Therapeutics (DNTH) stake by 55% in Q1 2026, buying an estimated $1.65M and bringing the position to 80,001 shares worth $6.71M. The position accounts for ﹤0.01% of the portfolio, ranked #3738.

Susquehanna International Group first reported a position in DNTH in Q3 2019 and has held it in 17 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Susquehanna International Group held 80,001 shares of Dianthus Therapeutics worth $6.71M as of Q1 2026.
  • Susquehanna International Group bought 28,535 Dianthus Therapeutics shares in Q1 2026, an estimated $1.65M.
  • Dianthus Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3738 holding.
  • Susquehanna International Group first reported a position in Dianthus Therapeutics in Q3 2019 and has held it in 17 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.